These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33208580)

  • 21. Outcome of Patients With In-Hospital Ventricular Tachycardia and Ventricular Fibrillation Arrest While Using a Wearable Cardioverter Defibrillator.
    Ellenbogen KA; Wan C; Shavelle DM
    Am J Cardiol; 2018 Jan; 121(2):205-209. PubMed ID: 29153771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
    Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O
    J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the implantable cardioverter-defibrillator: are we making progress?
    Weiss JN
    Heart Rhythm; 2008 Jun; 5(6 Suppl):S45-7. PubMed ID: 18456201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    Clin Cardiol; 2017 Aug; 40(8):586-590. PubMed ID: 28333373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable cardioverter defibrillator as therapeutic option for sudden cardiac death secondary to severe coronary vasospasm.
    Fuertes J; Gallego P; Peinado R; Merino JL
    Int J Cardiol; 1998 Jan; 63(2):181-3. PubMed ID: 9510493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence rather than costs must guide use of the implantable cardioverter defibrillator.
    Delacretaz E; Schlaepfer J; Metzger J; Fromer M; Kappenberger L
    Am J Cardiol; 2000 Nov; 86(9A):52K-57K. PubMed ID: 11084101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation.
    Kuck KH
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):713-20; discussion 720. PubMed ID: 20009082
    [No Abstract]   [Full Text] [Related]  

  • 31. The Wearable Cardioverter-Defibrillator in Newly Diagnosed Cardiomyopathy: Treatment on the Basis of Perceived Risk.
    Epstein AE
    J Am Coll Cardiol; 2015 Dec; 66(23):2614-2617. PubMed ID: 26670061
    [No Abstract]   [Full Text] [Related]  

  • 32. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
    Stiles MK; Fauchier L; Morillo CA; Wilkoff BL;
    Europace; 2019 Sep; 21(9):1442-1443. PubMed ID: 31090914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience.
    Sasaki S; Shoji Y; Ishida Y; Kinjo T; Tsushima Y; Seno M; Nishizaki F; Itoh T; Izumiyama K; Yokota T; Yokoyama H; Yamada M; Horiuchi D; Kimura M; Higuma T; Tomita H; Okumura K
    J Cardiol; 2017 Jan; 69(1):359-363. PubMed ID: 27595899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential proarrhythmic effects of implantable cardioverter-defibrillators.
    Duru F; Candinas R
    Clin Cardiol; 1999 Feb; 22(2):139-46. PubMed ID: 10068856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ventricular tachycardia and ventricular fibrillation.
    Srivathsan K; Ng DW; Mookadam F
    Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):801-9. PubMed ID: 19589116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG
    Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ventricular arrhythmias : What has been confirmed in therapy?].
    Duncker D; Bauersachs J; Veltmann C
    Internist (Berl); 2017 Dec; 58(12):1272-1280. PubMed ID: 29071387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.